ACC.16 | Volumes and Outcomes of TAVR

(4:28)

ACC.16 | TAVR vs. Surgery in Aortic Stenosis

(3:18)

ACC.16 | Valve Hemodynamic Deterioration

(3:14)

Highlights of New TAVR Research Presented at ACC 2016

(54)

Tsuyoshi Kaneko, MD: ACC TAVR Perspective

(8:45)

John-Daniel - 16 year old TAVR patient

(3:15)

PARTNER 2A and SAPIEN 3 Results: Future of TAVR

(21:16)

ACC House Call: Future TAVR Advances

(5:56)

1/22/16: Transcatheter Aortic Valve Replacement: “The most significant medical breakthrough?”

(55:2)

ACC.16 | INOVATE-HF Trial

(2:48)

TAVR and the Value of the STS/ACC TVT Registry

(22:15)

ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial

(3:47)

Relationship Between Procedure Volume and Outcome for TAVR

(8:4)

ACC.16 | PARTNER 2A Trial

(4:3)

Heart Minute | TAVR Outcomes in Patients With MR

(1:44)

TAVR for All: 'A Day That Patients Should Celebrate'

(4:21)

NCDR: Valve Hemodynamic Deterioration in TAVR Patients

(5:16)

TAVR Update 2016

(23:32)

Three-Year Outcomes in High-Risk Patients Undergoing SAVR or TAVR

(6:55)

Two Papers Look at TAVR vs. SAVR in Intermediate-Risk Patients

(6:37)